223 related articles for article (PubMed ID: 22374841)
1. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Fredly H; Reikvam H; Gjertsen BT; Bruserud O
Am J Hematol; 2012 Apr; 87(4):368-76. PubMed ID: 22374841
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.
Fredly H; Ersvær E; Gjertsen BT; Bruserud O
Oncol Rep; 2011 Jun; 25(6):1549-56. PubMed ID: 21431284
[TBL] [Abstract][Full Text] [Related]
3. Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.
Ersvaer E; Brenner AK; Vetås K; Reikvam H; Bruserud Ø
BMC Pharmacol Toxicol; 2015 May; 16():12. PubMed ID: 25934555
[TBL] [Abstract][Full Text] [Related]
4. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Reikvam H; Hatfield KJ; Ersvaer E; Hovland R; Skavland J; Gjertsen BT; Petersen K; Bruserud O
Br J Haematol; 2012 Feb; 156(4):468-80. PubMed ID: 22150087
[TBL] [Abstract][Full Text] [Related]
5. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.
Reikvam H; Nepstad I; Sulen A; Gjertsen BT; Hatfield KJ; Bruserud Ø
Expert Opin Investig Drugs; 2013 May; 22(5):551-63. PubMed ID: 23586877
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Raffoux E; Chaibi P; Dombret H; Degos L
Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
[TBL] [Abstract][Full Text] [Related]
8. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
Ryningen A; Stapnes C; Lassalle P; Corbascio M; Gjertsen BT; Bruserud O
Leuk Res; 2009 Jun; 33(6):779-87. PubMed ID: 19007987
[TBL] [Abstract][Full Text] [Related]
9. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
Reikvam H; Hovland R; Forthun RB; Erdal S; Gjertsen BT; Fredly H; Bruserud Ø
BMC Cancer; 2017 Sep; 17(1):630. PubMed ID: 28877686
[TBL] [Abstract][Full Text] [Related]
10. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Qi H; Ratnam M
Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
[TBL] [Abstract][Full Text] [Related]
12. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.
Grønningsæter IS; Fredly HK; Gjertsen BT; Hatfield KJ; Bruserud Ø
Cells; 2019 Oct; 8(10):. PubMed ID: 31658693
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
Bellos F; Mahlknecht U
Onkologie; 2008 Nov; 31(11):629-33. PubMed ID: 19145098
[TBL] [Abstract][Full Text] [Related]
18. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
[TBL] [Abstract][Full Text] [Related]
19. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
20. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
Poggi A; Catellani S; Garuti A; Pierri I; Gobbi M; Zocchi MR
Leukemia; 2009 Apr; 23(4):641-8. PubMed ID: 19151770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]